Literature DB >> 25107284

Treatment of cognitive dysfunction in major depressive disorder--a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine.

Alan L Pehrson1, Steven C Leiser2, Maria Gulinello3, Elena Dale2, Yan Li4, Jessica A Waller4, Connie Sanchez4.   

Abstract

Although major depressive disorder is primarily considered a mood disorder, depressed patients commonly present with clinically significant cognitive dysfunction that may add to their functional disability. This review paper summarizes the available preclinical data on the effects of antidepressants, including monoamine reuptake inhibitors and the multimodal antidepressant vortioxetine, in behavioral tests of cognition such as cognitive flexibility, attention, and memory, or in potentially cognition-relevant mechanistic assays such as electroencephalography, in vivo microdialysis, in vivo or in vitro electrophysiology, and molecular assays related to neurogenesis or synaptic sprouting. The available data are discussed in context with clinically relevant doses and their relationship to target occupancy levels, in order to evaluate the translational relevance of preclinical doses used during testing. We conclude that there is preclinical evidence suggesting that traditional treatment with monoamine reuptake inhibitors can induce improved cognitive function, for example in cognitive flexibility and memory, and that the multimodal-acting antidepressant vortioxetine may have some advantages by comparison to these treatments. However, the translational value of the reviewed preclinical data can be questioned at times, due to the use of doses outside the therapeutically-relevant range, the lack of data on target engagement or exposure, the tendency to investigate acute rather than long term antidepressant administration, and the trend towards using normal rodents rather than models with translational relevance for depression. Finally, several suggestions are made for advancing this field, including expanded use of target occupancy assessments in preclinical and clinical experiments, and the use of translationally valuable techniques such as electroencephalography.
Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cognitive function; Electrophysiology; Lu AA21004; Major depressive disorder; Receptor occupancy; Vortioxetine

Mesh:

Substances:

Year:  2014        PMID: 25107284     DOI: 10.1016/j.ejphar.2014.07.044

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  18 in total

1.  Depression severity and concentration difficulties are independently associated with HRQOL in patients with unipolar depressive disorders.

Authors:  A Fattori; L Neri; A Bellomo; M Vaggi; C Mencacci
Journal:  Qual Life Res       Date:  2017-05-13       Impact factor: 4.147

Review 2.  A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples.

Authors:  Catherine E Prado; Stephanie Watt; Simon F Crowe
Journal:  Neuropsychol Rev       Date:  2018-02-14       Impact factor: 7.444

3.  Paroxetine versus Vortioxetine for Depressive Symptoms in Postmenopausal Transition: A Preliminary Study.

Authors:  Camilla Callegari; Marta Ielmini; Ivano Caselli; Giulia Lucca; Celeste Isella; Marcello Diurni; Fabiana Pettenon; Nicola Poloni
Journal:  Psychopharmacol Bull       Date:  2019-02-15

4.  Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression.

Authors:  Kristian Gaarn du Jardin; Nico Liebenberg; Heidi Kaastrup Müller; Betina Elfving; Connie Sanchez; Gregers Wegener
Journal:  Psychopharmacology (Berl)       Date:  2016-05-28       Impact factor: 4.530

5.  A longitudinal study of cognitive trajectories in Mexican Americans age 75 and older.

Authors:  Brian Downer; Nai-Wei Chen; Mukaila Raji; Kyriakos S Markides
Journal:  Int J Geriatr Psychiatry       Date:  2016-09-06       Impact factor: 3.485

6.  Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism.

Authors:  Steven C Leiser; Deborah Iglesias-Bregna; Ligia Westrich; Alan L Pehrson; Connie Sanchez
Journal:  J Psychopharmacol       Date:  2015-07-14       Impact factor: 4.153

Review 7.  Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants.

Authors:  Alan L Pehrson; Connie Sanchez
Journal:  Drug Des Devel Ther       Date:  2015-01-19       Impact factor: 4.162

8.  A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.

Authors:  Atul R Mahableshwarkar; John Zajecka; William Jacobson; Yinzhong Chen; Richard S E Keefe
Journal:  Neuropsychopharmacology       Date:  2015-02-17       Impact factor: 7.853

9.  Vortioxetine administration attenuates cognitive and synaptic deficits in 5×FAD mice.

Authors:  Li-Xin Jiang; Geng-Di Huang; Feng Su; Huali Wang; Chen Zhang; Xin Yu
Journal:  Psychopharmacology (Berl)       Date:  2020-01-18       Impact factor: 4.530

10.  The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials.

Authors:  R S McIntyre; J Harrison; H Loft; W Jacobson; C K Olsen
Journal:  Int J Neuropsychopharmacol       Date:  2016-06-15       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.